In this study, we aimed to present our data on the validation of cfDNA as a diagnostic approach for screening somatic mutations or hotspot mutations in EGFR gene (exons 18, 19, and 21) among NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.